海外招聘者

2025年8月28日時点
アルファベット順・敬称略

	Hanny Al-Samkari The Peggy S. Blitz Endowed Chair in Hematology/Oncology, Massachusetts General Hospital Harvard Medical School, USA 【Speaker】Symposium 6 Risk of Thrombosis in unexpected places
	Belinda Avalos Atrium Health Levine Cancer Institute, USA 【Speaker】ASH Special Lecture Germ line CSF3R mutations in CNL 【Chair】JSH-ASH Joint Symposium Recent advances in molecular pathogenesis of acute leukemia 【Commentator】SETP 1 Cellular immunotherapy for hematological malignancies
	Prithviraj Bose University of Texas MD Anderson Cancer Center, USA 【Speaker】Symposium 5 Development of novel therapies for myeloproliferative neoplasms
	Robert Bradley Fred Hutchinson Cancer Center, USA 【Speaker】JSH-ASH Joint Symposium Recent advances in molecular pathogenesis of acute leukemia
	Nina Cabezas-Wallscheid Swiss Federal Institute of Technology (ETH Zürich), Zürich, Switzerland 【Speaker】Symposium 2 Energy acquisition in hematopoietic stem cells
	Hartmut Döhner Ulm University Hospital, Germany 【Speaker】Special Lecture 1 Molecular Genetics Guiding Treatment in Acute Myeloid Leukemia
	Konstanze Döhner University Hospital of Ulm, Germany 【Speaker】EHA Special Lecture Molecular monitoring of measurable residual disease (MRD) in acute myeloid leukemia (AML) 【Chair】JSH-EHA Joint Symposium Development of Novel Therapies to Prevent Post-Transplant Recurrence
	Lorenzo Falchi Memorial Sloan-Kettering Cancer Center, USA 【Chair】【Speaker】Symposium 1 Emerging treatment for B cell lymphoma 【Commentator】SETP 4 Novel therapeutic strategies for malignant lymphoma
	Mirco J Friedrich Broad Institute of MIT and Harvard, USA 【Speaker】Symposium 8 Importance of T cell fitness in cancer immunotherapy
	Zinaida Good Stanford University, USA 【Chair】【Speaker】Symposium 8 Importance of T cell fitness in cancer immunotherapy
	Emily Heikamp Dana-Farber Cancer Institute/Harvard Medical School, USA 【Speaker】JSH-ASH Joint Symposium Recent advances in molecular pathogenesis of acute leukemia 【Commentator】SETP 3 Molecular targets for the treatment of AML
	Than Hein National Cancer Centre Singapore, Singapore General Hospital, Singapore 【Speaker】Asian Joint Panel Discussion Novel therapeutic approaches for refractory hematological malignancies
	Keisuke Ito Albert Einstein College of Medicine, USA 【Speaker】Symposium 2 Energy acquisition in hematopoietic stem cells
	Seok-Jin Kim Sungkyunkwan University School of Medicine, Samsung Medical Center, Korea 【Chair】Asian Joint Panel Discussion Novel therapeutic approaches for refractory hematological malignancies
	Youngil Koh Department of Internal Medicine, Seoul National University Hospital ,Korea 【Speaker】Asian Joint Panel Discussion Novel therapeutic approaches for refractory hematological malignancies
	Stephanie Lee Clinical Research Division Fred Hutchinson Cancer Center, USA 【Speaker】Special Lecture 2 Novel treatment strategies for chronic GVHD after allogeneic HCT 【Speaker】Women Physicians Career Symposium
	Mark Levis Johns Hopkins University, USA 【Speaker】Presidential Symposium Therapeutic strategy for AML with FLT3 mutations
	Jia-Hau Liu Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan 【Speaker】Asian Joint Panel Discussion Novel therapeutic approaches for refractory hematological malignancies
	David Malkin Division of Hematology/Oncology, The Hospital for Sick Children, Canada 【Speaker】Symposium 7 Understanding germline findings in the era of genomic medicine
	Dimitrios C. Mastellos National Center for Scientific Research "Demokritos", GREECE 【Speaker】Symposium 3 Exploring the Complement System in Hematology: Biological Insights and Emerging Therapeutic Prospects
	Krina K. Patel The University of Texas MD Anderson Cancer Center, USA 【Speaker】Symposium 4 Cutting edge of genetic basis and current immune therapies in multiple myeloma
	Kannadit Prayongratana Phramongkutklao Hospital, Thailand 【Speaker】Asian Joint Panel Discussion Novel therapeutic approaches for refractory hematological malignancies
	Mark Roschewski National Cancer Institute, USA 【Speaker】Symposium 1 Emerging treatment for B cell lymphoma
	Mehmet Samur Dana Farber Cancer Institute & Harvard TH Chan School of Public Health, USA 【Speaker】Symposium 4 Cutting edge of genetic basis and current immune therapies in multiple myeloma 【Commentator】SETP 2 Molecular Pathogenesis of Multiple Myeloma
	Christoph Schmidt University of Ulm Medical Center, Germany 【Speaker】Symposium 3 Exploring the Complement System in Hematology: Biological Insights and Emerging Therapeutic Prospects
	Avinash Kumar Singh Paras HMRI Hospital, India 【Speaker】Asian Joint Panel Discussion Novel therapeutic approaches for refractory hematological malignancies
	Catherine C. Smith University of California, San Francisco, USA 【Speaker】Presidential Symposium Therapeutic strategy for AML with FLT3 mutations
	Xiaowen Tang The First Affiliated Hospital of Soochow University, China 【Speaker】Asian Joint Panel Discussion Novel therapeutic approaches for refractory hematological malignancies
	Luca Vago San Raffaele Scientific Institute, Italy 【Speaker】JSH-EHA Joint Symposium Development of Novel Therapies to Prevent Post-Transplant Recurrence
	Nan Wang Columbia University Irving Medical Center, USA 【Speaker】Symposium 6 Risk of Thrombosis in unexpected places
	Wei-Li Zhao Shanghai Institute of Hematology, China 【Speaker】Symposium 1 Emerging treatment for B cell lymphoma